05-04-2025 | Atrial Fibrillation

Left atrial appendage occlusion in patients with cancer

Authors: Nathaniel E. Davis, Samuel A. Shabtaie, Nicholas Y. Tan

Published in: Journal of Thrombosis and Thrombolysis

Abstract

Atrial fibrillation (AF) and malignancy share a complex relationship, significantly complicating patient management. Patients with cancer, particularly those with lung, gastrointestinal, genitourinary, and hematologic malignancies, are at increased risk of AF due to cancer-related hypercoagulability, proinflammatory cytokines, and treatment-related factors. This population faces unique thrombotic and bleeding risks, challenging standard management approaches. Anticoagulation is often complicated by drug-drug interactions with cancer therapies and heightened bleeding risks, including thrombocytopenia and coagulopathy. Left atrial appendage occlusion (LAAO) offers an alternative stroke prevention strategy for patients unable to tolerate long-term anticoagulation. By isolating the left atrial appendage, LAAO reduces thromboembolic risk while minimizing bleeding complications. Indications include patients with elevated stroke risk with contraindications to anticoagulation due to nonreversible causes, such as recurrent bleeding or significant drug interactions. Surgical LAAO may also be considered during cardiac surgery in patients with AF and high thromboembolic risk, with previous studies showing reduced risk of thromboembolic complications. Outcomes of LAAO in cancer patients are generally favorable, with studies showing comparable stroke rates, bleeding risks, and mortality to non-cancer populations. However, malignancy-specific complications, such as device-related thrombus, require further investigation. LAAO provides a promising option for stroke prevention in this complex population, but further research is needed to refine patient selection and optimize outcomes.

Chen Q, van Rein N, van der Hulle T, Heemelaar JC, Trines SA, Versteeg HH et al (2024) Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study. Eur Heart J. https://doi.org/10.1093/eurheartj/ehae222CrossRefPubMedPubMedCentral

Madnick DL, Fradley MG (2022) Atrial fibrillation and cancer patients: mechanisms and management. Curr Cardiol Rep 24:1517–1527. https://doi.org/10.1007/s11886-022-01769-3CrossRefPubMed

Vinter N, Christesen AMS, Fenger-Grøn M, Tjønneland A, Frost L Atrial fibrillation and risk of cancer: A Danish Population‐Based cohort study. J Am Heart Assoc 2018;7. https://doi.org/10.1161/JAHA.118.009543

Ostenfeld EB, Erichsen R, Pedersen L, Farkas DK, Weiss NS, Sørensen HT (2014) Atrial fibrillation as a marker of occult cancer. PLoS ONE 9:e102861. https://doi.org/10.1371/journal.pone.0102861CrossRefPubMedPubMedCentral

Huang W, Xu S, Zhou H, Ji W, Chen Y (2024) Global association of incidence between atrial fibrillation and the major Gastrointestinal cancers: an analysis based on the 2019 global burden of disease study. Heliyon 10:e29929. https://doi.org/10.1016/j.heliyon.2024.e29929CrossRefPubMedPubMedCentral

Raposeiras Roubín S, Abu Assi E, Barreiro Pardal C, Cespón Fernandez M, Muñoz Pousa I, Cobas Paz R et al (2020) New cancer diagnosis after bleeding in anticoagulated patients with atrial fibrillation. J Am Heart Assoc 9. https://doi.org/10.1161/JAHA.120.016836

Lateef N, Kapoor V, Ahsan MJ, Latif A, Ahmed U, Mirza M et al (2020) Atrial fibrillation and cancer; Understanding the mysterious relationship through a systematic review. J Community Hosp Intern Med Perspect 10:127–132. https://doi.org/10.1080/20009666.2020.1726571CrossRefPubMedPubMedCentral

Yuan M, Zhang Z, Tse G, Feng X, Korantzopoulos P, Letsas KP et al (2019) Association of cancer and the risk of developing atrial fibrillation: A systematic review and Meta-Analysis. Cardiol Res Pract 2019:1–9. https://doi.org/10.1155/2019/8985273CrossRef

Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J et al (2010) Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer 103:947–953. https://doi.org/10.1038/sj.bjc.6605883CrossRefPubMedPubMedCentral

10.

Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F et al (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137:1959–1969. https://doi.org/10.1182/blood.2020007338CrossRefPubMed

11.

Noble S, Pasi J (2010) Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 102:S2–9. https://doi.org/10.1038/sj.bjc.6605599CrossRefPubMedPubMedCentral

12.

Pastori D, Marang A, Bisson A, Menichelli D, Herbert J, Lip GYH et al (2021) Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. Cancer 127:2122–2129. https://doi.org/10.1002/cncr.33470CrossRefPubMed

13.

Elbadawi A, Elgendy IY, Ha LD, Baig B, Saad M, Adly H et al (2018) In-Hospital cerebrovascular outcomes of patients with atrial fibrillation and cancer (from the National inpatient sample Database). Am J Cardiol 121:590–595. https://doi.org/10.1016/j.amjcard.2017.11.027CrossRefPubMed

14.

Hu W-S, Lin C-L (2018) Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHA2DS2-VASc score-a nationwide cohort study. Oncotarget 9:7623–7630. https://doi.org/10.18632/oncotarget.24143CrossRefPubMedPubMedCentral

15.

Wang C-L, Wu VC-C, Tu H-T, Huang Y-T, Chen S-W, Chu P-H et al (2022) Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation. J Thromb Thrombolysis 53:633–645. https://doi.org/10.1007/s11239-021-02570-9CrossRefPubMed

16.

Hellfritzsch M, Henriksen JN, Holt MI, Grove EL (2024) Drug–Drug interactions in the treatment of Cancer-Associated venous thromboembolism with direct oral anticoagulants. Semin Thromb Hemost 50:489–498. https://doi.org/10.1055/s-0043-1762596CrossRefPubMed

17.

Truong B, Hornsby L, Fox B, Chou C, Zheng J, Qian J Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and cancer: A target trial emulation from SEER-Medicare database. Cardiovasc Drugs Ther 2024. https://doi.org/10.1007/s10557-024-07589-7

18.

Saw J, Holmes DR, Cavalcante JL, Freeman JV, Goldsweig AM, Kavinsky CJ et al (2023) SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. Heart Rhythm 20:e1–16. https://doi.org/10.1016/j.hrthm.2023.01.007CrossRefPubMed

19.

Ghodrati-Misek M, Schlöglhofer T, Gross C, Maurer A, Zimpfer D, Beitzke D et al (2022) Left atrial appendage occlusion in ventricular assist device patients to decrease thromboembolic events: A computer simulation study. Front Physiol 13. https://doi.org/10.3389/fphys.2022.1010862

20.

Cha MJ, An D-G, Kang M, Kim HM, Kim S-W, Cho I et al (2023) Correct closure of the left atrial appendage reduces stagnant blood flow and the risk of thrombus formation: A Proof-of-Concept experimental study using 4D flow magnetic resonance imaging. Korean J Radiol 24:647. https://doi.org/10.3348/kjr.2023.0173CrossRefPubMedPubMedCentral

21.

Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM et al 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 2024;149. https://doi.org/10.1161/CIR.0000000000001193

22.

Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J et al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2:3257–3291. https://doi.org/10.1182/bloodadvances.2018024893CrossRefPubMedPubMedCentral

23.

Lafaie L, Hodin S, Saïb S, Bin V, Bertoletti L, Delavenne X (2022) Tyrosine kinase inhibitors and direct oral anticoagulants: in vitro evaluation of drug–drug interaction mediated by P-glycoprotein. Fundam Clin Pharmacol 36:860–868. https://doi.org/10.1111/fcp.12769CrossRefPubMed

24.

Fang B, Jin S, Du W, Cai W (2023) Anlotinib and fruquintinib co-administrated with warfarin increases the risk of bleeding: studied from Pharmacokinetic and pharmacodynamic perspectives. Eur J Pharm Sci 188:106507. https://doi.org/10.1016/j.ejps.2023.106507CrossRefPubMed

25.

Hasegawa A, Tsujiya Y, Ueda A, Yamamori M, Okamura N (2022) In vivo evaluation of Pharmacokinetic drug–drug interactions between fluorinated pyrimidine anticancer drugs, 5-fluorouracil and Capecitabin, and an anticoagulant, warfarin. Xenobiotica 52:608–612. https://doi.org/10.1080/00498254.2022.2118643CrossRefPubMed

26.

von Wyler MC, Hui DS, Mehaffey JH, Malaisrie SC, Vardas PN, Gillinov AM et al (2024) The society of thoracic surgeons 2023 clinical practice guidelines for the surgical treatment of atrial fibrillation. Ann Thorac Surg 118:291–310. https://doi.org/10.1016/j.athoracsur.2024.01.007CrossRef

27.

Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M et al (2021) Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 384:2081–2091. https://doi.org/10.1056/NEJMoa2101897CrossRefPubMed

28.

Mc Cormack O, Zaborowski A, King S, Healy L, Daly C, O’Farrell N et al (2014) New-onset atrial fibrillation Post-surgery for esophageal and junctional cancer. Ann Surg 260:772–778. https://doi.org/10.1097/SLA.0000000000000960CrossRefPubMed

29.

Semeraro GC, Meroni CA, Cipolla CM, Cardinale DM (2021) Atrial fibrillation after lung cancer surgery: prediction, prevention and anticoagulation management. Cancers (Basel) 13:4012. https://doi.org/10.3390/cancers13164012CrossRefPubMed

30.

Fabiani I, Colombo A, Bacchiani G, Cipolla CM, Cardinale DM, Incidence (2019) Management, prevention and outcome of Post-Operative atrial fibrillation in thoracic surgical oncology. J Clin Med 9:37. https://doi.org/10.3390/jcm9010037CrossRefPubMedPubMedCentral

31.

Toale C, Jones J, Fitzmaurice GJ, Eaton D (2019) Left atrial appendage clipping as an adjunctive therapy in lung cancer surgery for patients with atrial fibrillation: a case report. J Surg Case Rep 2019:rjz298. https://doi.org/10.1093/jscr/rjz298CrossRefPubMedPubMedCentral

32.

Yang M, Chen M, Gong C-Q, Li W, Zhang P-P, Zhang R et al (2023) Left atrial appendage closure in patients with reversed chicken-wing morphology: anatomical features and procedural strategy. Heliyon 9:e12662. https://doi.org/10.1016/j.heliyon.2022.e12662CrossRefPubMedPubMedCentral

33.

Lu X, Chen T, Liu G, Guo Y, Shi X, Chen Y et al (2022) Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation. J Thromb Thrombolysis 53:191–201. https://doi.org/10.1007/s11239-021-02490-8CrossRefPubMed

34.

Chen Z, Bai W, Li C, Wang H, Tang H, Qin Y et al (2017) Left atrial appendage parameters assessed by Real-Time Three-Dimensional transesophageal echocardiography predict thromboembolic risk in patients with nonvalvular atrial fibrillation. J Ultrasound Med 36:1119–1128. https://doi.org/10.7863/ultra.16.05070CrossRefPubMed

35.

Xu B, Du Y, Xu C, Sun Y, Peng F, Wang S et al (2021) Left atrial appendage morphology and local Thrombogenesis-Related blood parameters in patients with atrial fibrillation. J Am Heart Assoc 10. https://doi.org/10.1161/JAHA.120.020406

36.

LÓPEZ-MÍNGUEZ R JR, FERNÁNDEZ‐VEGAS C, MILLÁN‐NUÑEZ V, FUENTES‐CAÑAMERO ME, NOGALES‐ASENSIO JM et al (2014) Anatomical classification of left atrial appendages in specimens applicable to CT imaging techniques for implantation of amplatzer cardiac plug. J Cardiovasc Electrophysiol 25:976–984. https://doi.org/10.1111/jce.12429

37.

Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P et al Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: A scientific statement from the American heart association. Circulation 2018;137. https://doi.org/10.1161/CIR.0000000000000568

38.

Tiver KD, Quah J, Lahiri A, Ganesan AN, McGavigan AD (2021) Atrial fibrillation burden: an update—the need for a CHA2DS2-VASc-AFBurden score. EP Europace 23:665–673. https://doi.org/10.1093/europace/euaa287CrossRefPubMed

39.

Kommu S, Sharma PP (2024) Subclinical atrial fibrillation: to anticoagulate or not?? J Clin Med 13:3236. https://doi.org/10.3390/jcm13113236CrossRefPubMedPubMedCentral

40.

Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF et al (2024) Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 390:107–117. https://doi.org/10.1056/NEJMoa2310234CrossRefPubMed

41.

Boriani G, Gerra L, Mei DA, Bonini N, Vitolo M, Proietti M et al (2024) Detection of subclinical atrial fibrillation with cardiac implanted electronic devices: what decision making on anticoagulation after the NOAH and artesia trials? Eur J Intern Med 123:37–41. https://doi.org/10.1016/j.ejim.2024.01.002CrossRefPubMed

42.

Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N et al (2023) Anticoagulation with Edoxaban in patients with atrial High-Rate episodes. N Engl J Med 389:1167–1179. https://doi.org/10.1056/NEJMoa2303062CrossRefPubMed

43.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV et al (2017) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70:926–938. https://doi.org/10.1016/j.jacc.2017.06.047CrossRefPubMedPubMedCentral

44.

Verso M, Agnelli G, Munoz A, Connors JM, Sanchez O, Huisman M et al (2022) Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. Eur J Cancer 165:136–145. https://doi.org/10.1016/j.ejca.2022.01.023CrossRefPubMed

45.

Uno H, Xiong H, Cronin C, Schrag D, Connors JM (2024) Predictors of recurrent venous thromboembolism and major bleeding in patients with cancer: A secondary analysis of the CANVAS trial. Thromb Res 244:109184. https://doi.org/10.1016/j.thromres.2024.109184CrossRefPubMed

46.

Ajabnoor AM, Parisi R, Zghebi SS, Ashcroft DM, Faivre-Finn C, Morris C et al (2023) Common cancer types and risk of stroke and bleeding in patients with nonvalvular atrial fibrillation: A Population‐Based study in England. J Am Heart Assoc 12. https://doi.org/10.1161/JAHA.123.029423

47.

Vedovati MC, Giustozzi M, Munoz A, Bertoletti L, Cohen AT, Klok FA et al (2023) Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism. Eur J Intern Med 112:29–36. https://doi.org/10.1016/j.ejim.2023.02.003CrossRefPubMed

48.

Zweiker D, Bergler-Klein J, Fiedler L, Toth GG, Achleitner R, Schratter A et al (2024) Left atrial appendage closure in atrial fibrillation patients with cancer. J Clin Med 13:6514. https://doi.org/10.3390/jcm13216514CrossRefPubMedPubMedCentral

49.

Kumar S, Yoon S, Milioglou I, Tashtish N, Farmakis I, Dallan LAP et al (2023) Left atrial appendage closure outcomes in patients with cancer at a single tertiary center. Am J Cardiol 202:176–181. https://doi.org/10.1016/j.amjcard.2023.06.068CrossRefPubMed

50.

Gallo F, Ronco F, D’Amico G, Della Rocca DG, Mazzone P, Bordignon S et al (2023) Clinical outcomes of left atrial appendage occlusion in patients with previous intracranial or Gastrointestinal bleeding: insights from the LOGIC (Left atrial appendage occlusion in patients with Gastrointestinal or intracranial bleeding) international multicenter registry. Catheter Cardiovasc Interv 101:1144–1153. https://doi.org/10.1002/ccd.30629CrossRefPubMed

51.

Zieliński K, Pracoń R, Konka M, Kruk M, Kępka C, Trochimiuk P et al (2022) Incidence and predictors of clinically significant bleedings after transcatheter left atrial appendage closure. Int J Environ Res Public Health 19:13802. https://doi.org/10.3390/ijerph192113802CrossRefPubMedPubMedCentral

52.

López-Mínguez JR, Nogales-Asensio JM, Infante De Oliveira E, Santos L, Ruiz-Salmerón R, Arzamendi-Aizpurua D et al (2020) Major bleeding predictors in patients with left atrial appendage closure: the Iberian registry II. J Clin Med 9:2295. https://doi.org/10.3390/jcm9072295CrossRefPubMedPubMedCentral

53.

Lempereur M, Aminian A, Freixa X, Gafoor S, Shakir S, Omran H et al (2017) Left atrial appendage occlusion in patients with atrial fibrillation and previous major Gastrointestinal bleeding (from the amplatzer cardiac plug multicenter Registry). Am J Cardiol 120:414–420. https://doi.org/10.1016/j.amjcard.2017.04.046CrossRefPubMed

54.

Kowalska W, Mitręga K, Olma A, Podolecki T, Kalarus Z, Streb W (2023) Anticoagulants versus left atrial appendage occlusion in patients with atrial fibrillation and Co-Morbid thrombocytopenia. J Clin Med 12:7637. https://doi.org/10.3390/jcm12247637CrossRefPubMedPubMedCentral

55.

Zhang X, Jin Q, Hu J, Kong D, Pan C, Chen D et al (2021) Impact of thrombocytopenia in patients with atrial fibrillation undergoing left atrial appendage occlusion: A Propensity-Matched comparison of 190 consecutive watchman implantations. Front Cardiovasc Med 8. https://doi.org/10.3389/fcvm.2021.603501

56.

Drozdinsky G, Arad N, Spectre G, Livneh N, Poran I, Raanani P et al (2024) Anticoagulation in cancer patients with atrial fibrillation and grade 3–4 thrombocytopenia. Thromb Res 235:92–97. https://doi.org/10.1016/j.thromres.2024.01.012CrossRefPubMed

57.

Livneh N, Braeken D, Drozdinsky G, Gafter-Gvili A, Seelig J, Rozovski U et al (2021) Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy. J Thromb Thrombolysis 52:590–596. https://doi.org/10.1007/s11239-021-02393-8CrossRefPubMed

58.

Munir MB, Khan MZ, Darden D, Abideen Asad ZU, Osman M, Singh GD et al (2022) Association of heart failure with procedural complications and in-hospital outcomes from left atrial appendage occlusion device implantation in patients with atrial fibrillation: insights from the National inpatient sample of 62 980 procedures. EP Europace 24:1451–1459. https://doi.org/10.1093/europace/euac043CrossRefPubMed

59.

Das S, Lorente-Ros M, Wu L, Mehta D, Suri R (2022) Safety of left atrial appendage closure in heart failure patients. J Cardiovasc Electrophysiol 33:2578–2584. https://doi.org/10.1111/jce.15682CrossRefPubMed

60.

Zhao M, Hou CR, Bai J, Post F, Walsleben J, Herold N et al (2022) Effect of congestive heart failure on safety and efficacy of left atrial appendage closure in patients with non-valvular atrial fibrillation. Expert Rev Med Devices 19:805–814. https://doi.org/10.1080/17434440.2022.2141112CrossRefPubMed

61.

Lin AY, Dinatolo E, Metra M, Sbolli M, Dasseni N, Butler J et al (2021) Thromboembolism in heart failure patients in sinus rhythm. JACC Heart Fail 9:243–253. https://doi.org/10.1016/j.jchf.2021.01.009CrossRefPubMed

62.

Fanola CL, Norby FL, Shah AM, Chang PP, Lutsey PL, Rosamond WD et al (2020) Incident heart failure and Long-Term risk for venous thromboembolism. J Am Coll Cardiol 75:148–158. https://doi.org/10.1016/j.jacc.2019.10.058CrossRefPubMedPubMedCentral

63.

Königsbrügge O, Riedl J, Grilz E, Wiltschke C, Zielinski C, Pabinger I et al (2016) PO-01 - Congestive heart failure is an independent risk factor for venous thromboembolism and mortality in cancer patients. Thromb Res 140:S176. https://doi.org/10.1016/S0049-3848(16)30134-7CrossRefPubMed

64.

Kadowaki H, Akazawa H, Shindo A, Ueda T, Ishida J, Komuro I (2024) Shared and reciprocal mechanisms between heart failure and cancer ― an emerging concept of heart-Cancer axis ―. Circ J 88. https://doi.org/10.1253/circj.CJ-23-0838.:CJ-23-0838

65.

Bhat FA, Khan S, Khan AS, Haque SE, Akhtar M, Najmi AK (2024) Cardio-oncological dialogue: Understanding the mechanistic correlation between heart failure and cancer. Life Sci 358:123170. https://doi.org/10.1016/j.lfs.2024.123170CrossRefPubMed

66.

Jaiswal V, Ang SP, Shrestha AB, Wajid Z, Endurance EO, Ayoobkhan FS et al (2023) Amplatzer amulet versus watchman device for percutaneous left atrial appendage closure: A systematic review and meta-analysis. Medicine 102:e34185. https://doi.org/10.1097/MD.0000000000034185CrossRefPubMedPubMedCentral

67.

Lakkireddy D, Thaler D, Ellis CR, Swarup V, Sondergaard L, Carroll J et al (2021) Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE): A randomized, controlled trial. Circulation 144:1543–1552. https://doi.org/10.1161/CIRCULATIONAHA.121.057063CrossRefPubMedPubMedCentral

68.

Galea R, De Marco F, Meneveau N, Aminian A, Anselme F, Gräni C et al (2022) Amulet or watchman device for percutaneous left atrial appendage closure: primary results of the SWISS-APERO randomized clinical trial. Circulation 145:724–738. https://doi.org/10.1161/CIRCULATIONAHA.121.057859CrossRefPubMed

69.

Lakkireddy D, Ellis CR, Thaler D, Swarup V, Gambhir A, Hermiller J et al (2024) 5-Year results from the AMPLATZER amulet left atrial appendage occluder randomized controlled trial. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2024.10.101CrossRefPubMed

70.

Shabtaie SA, Tan NY, Ward RC, Lewis BR, Yang EH, Holmes DR et al (2023) Left atrial appendage occlusion in patients with atrial fibrillation and cancer. JACC CardioOncol 5:203–212. https://doi.org/10.1016/j.jaccao.2022.10.016CrossRefPubMedPubMedCentral

71.

Sommer RJ, Lamport R, Melanson D, Devellian C, Levine A, Cain CM et al Preclinical assessment of a novel conformable Foam-Based left atrial appendage closure device. Biomed Res Int 2021;2021. https://doi.org/10.1155/2021/4556400

72.

Sommer RJ, Kim JH, Szerlip M, Chandhok S, Sugeng L, Cain C et al (2021) Conformal left atrial appendage seal device for left atrial appendage closure. JACC Cardiovasc Interv 14:2368–2374. https://doi.org/10.1016/j.jcin.2021.08.060CrossRefPubMed

73.

Betts TR, Leo M, Panikker S, Kanagaratnam P, Koa-Wing M, Davies DW et al (2017) Percutaneous left atrial appendage occlusion using different technologies in the united Kingdom: A multicenter registry. Catheter Cardiovasc Interv 89:484–492. https://doi.org/10.1002/ccd.26782CrossRefPubMed

74.

Lip GYH, Banerjee A, Boriani G, Chiang C en, Fargo R, Freedman B et al (2018) Antithrombotic therapy for atrial fibrillation. Chest 154:1121–1201. https://doi.org/10.1016/j.chest.2018.07.040CrossRefPubMed

75.

Blackshear JL, Odell JA (1996) Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 61:755–759. https://doi.org/10.1016/0003-4975(95)00887-XCrossRefPubMed

76.

Caliskan E, Sahin A, Yilmaz M, Seifert B, Hinzpeter R, Alkadhi H et al (2018) Epicardial left atrial appendage atriclip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. EP Europace 20:e105–e114. https://doi.org/10.1093/europace/eux211CrossRefPubMed

77.

Rhee Y, Park SJ, Lee JW (2023) Epicardial left atrial appendage clip occlusion in patients with atrial fibrillation during minimally invasive cardiac surgery. J Thorac Cardiovasc Surg 166:468–474. https://doi.org/10.1016/j.jtcvs.2021.10.032CrossRefPubMed

78.

Kiankhooy A, Liem B, Dunnington GH, Pierce C, Eisenberg SJ, Burk S et al (2022) Left atrial appendage ligation using the atriclip device: Single-Center study of device safety and efficacy. Innovations: Technol Techniques Cardiothorac Vascular Surg 17:209–216. https://doi.org/10.1177/15569845221091998CrossRef

79.

Tilz RR, Fink T, Bartus K, Wong T, Vogler J, Nentwich K et al (2020) A collective European experience with left atrial appendage suture ligation using the LARIAT + device. EP Europace 22:924–931. https://doi.org/10.1093/europace/euaa004CrossRef

80.

Price MJ, Gibson DN, Yakubov SJ, Schultz JC, Di Biase L, Natale A et al (2014) Early safety and efficacy of percutaneous left atrial appendage suture ligation. J Am Coll Cardiol 64:565–572. https://doi.org/10.1016/j.jacc.2014.03.057CrossRefPubMedPubMedCentral

81.

Bartus K, Han FT, Bednarek J, Myc J, Kapelak B, Sadowski J et al (2013) Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation. J Am Coll Cardiol 62:108–118. https://doi.org/10.1016/j.jacc.2012.06.046CrossRefPubMed

82.

Kanderian AS, Gillinov AM, Pettersson GB, Blackstone E, Klein AL (2008) Success of surgical left atrial appendage closure. J Am Coll Cardiol 52:924–929. https://doi.org/10.1016/j.jacc.2008.03.067CrossRefPubMed

83.

Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH et al (2005) Left atrial appendage occlusion study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 150:288–293. https://doi.org/10.1016/j.ahj.2004.09.054CrossRefPubMed

84.

Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK et al (2014) Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus Long-Term warfarin therapy. J Am Coll Cardiol 64:1–12. https://doi.org/10.1016/j.jacc.2014.04.029CrossRefPubMed

85.

Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P et al Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation. JAMA 2014;312:1988. https://doi.org/10.1001/jama.2014.15192

86.

Freeman JV, Higgins AY, Wang Y, Du C, Friedman DJ, Daimee UA et al (2022) Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation. J Am Coll Cardiol 79:1785–1798. https://doi.org/10.1016/j.jacc.2022.02.047CrossRefPubMedPubMedCentral

87.

Coylewright M, Holmes DR, Kapadia SR, Hsu JC, Gibson DN, Freeman JV et al (2023) DAPT is comparable to OAC following LAAC with WATCHMAN FLX. JACC Cardiovasc Interv 16:2708–2718. https://doi.org/10.1016/j.jcin.2023.08.013CrossRefPubMed

88.

Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B et al (2017) Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 14:1302–1308. https://doi.org/10.1016/j.hrthm.2017.05.038CrossRefPubMed

89.

Tzikas A, Gafoor S, Meerkin D, Freixa X, Cruz-Gonzalez I, Lewalter T et al (2016) Left atrial appendage occlusion with the AMPLATZER amulet device: an expert consensus step-by-step approach. EuroIntervention 11:1512–1521. https://doi.org/10.4244/EIJV11I13A292CrossRefPubMed

90.

Vuddanda VLK, Turagam MK, Umale NA, Shah Z, Lakkireddy DR, Bartus K et al (2020) Incidence and causes of in-hospital outcomes and 30-day readmissions after percutaneous left atrial appendage closure: A US nationwide retrospective cohort study using claims data. Heart Rhythm 17:374–382. https://doi.org/10.1016/j.hrthm.2019.09.018CrossRefPubMed

91.

Tinoco M, Echarte-Morales J, Guerreiro CE, Ávila Gil EM, Caneiro-Queija B, Barreiro-Pérez M et al (2025) Short- and long-term outcomes of percutaneous left atrial appendage occlusion in cancer patients. IJC Heart Vasculature 56:101585. https://doi.org/10.1016/j.ijcha.2024.101585CrossRefPubMed

92.

Zhang Y, Yang Z, Almani MU, Soon-Shiong R, Liu B (2023) Utilization and short-term outcomes of percutaneous left atrial appendage occlusion in patients with cancer. Cardio-Oncology 9:39. https://doi.org/10.1186/s40959-023-00192-zCrossRefPubMedPubMedCentral

93.

Simard T, Jung RG, Lehenbauer K, Piayda K, Pracoń R, Jackson GG et al (2021) Predictors of Device-Related thrombus following percutaneous left atrial appendage occlusion. J Am Coll Cardiol 78:297–313. https://doi.org/10.1016/j.jacc.2021.04.098CrossRefPubMed

94.

Sedaghat A, Vij V, Al-Kassou B, Gloekler S, Galea R, Fürholz M et al (2021) Device-Related thrombus after left atrial appendage closure: data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT-Registry. Circ Cardiovasc Interv 14. https://doi.org/10.1161/CIRCINTERVENTIONS.120.010195

95.

Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Abbey S et al (2018) Device-Related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol 71:1528–1536. https://doi.org/10.1016/j.jacc.2018.01.076CrossRefPubMed

96.

Dukkipati SR, Kar S, Holmes DR, Doshi SK, Swarup V, Gibson DN et al (2018) Device-Related thrombus after left atrial appendage closure. Circulation 138:874–885. https://doi.org/10.1161/CIRCULATIONAHA.118.035090CrossRefPubMed

97.

Osama M, Naeem N, ahmed asmaa, Chuprun D, Depta J, Rao M Abstract 4140981: In-Hospital outcomes of left atrial appendage occlusion (LAAO) among patients with atrial fibrillation and hematological malignancy; insight from the National inpatient database (2015–2020). Circulation 2024;150. https://doi.org/10.1161/circ.150.suppl_1.4140981

98.

Reinhardt SW, Gibson DN, Hsu JC, Kapadia SR, Yeh RW, Price MJ et al (2024) Anticoagulation alone vs anticoagulation plus aspirin or DAPT following left atrial appendage occlusion. J Am Coll Cardiol 84:889–900. https://doi.org/10.1016/j.jacc.2024.05.067CrossRefPubMed

99.

Wazni OM, Saliba WI, Nair DG, Marijon E, Schmidt B, Hounshell T et al (2024) Left atrial appendage closure after ablation for atrial fibrillation. N Engl J Med. https://doi.org/10.1056/NEJMoa2408308CrossRefPubMed

100.

Kapadia SR, Krishnaswamy A, Whisenant B, Potluri S, Iyer V, Aragon J et al (2024) Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation. Circulation 149:734–743. https://doi.org/10.1161/CIRCULATIONAHA.123.067312CrossRefPubMed

101.

Sun A, Ren S, Xiao Y, Chen Y, Wang N, Li C et al (2022) Real-time 3D echocardiographic transilluminated imaging combined with artificially intelligent left atrial appendage measurement for atrial fibrillation interventional procedures. Front Physiol 13. https://doi.org/10.3389/fphys.2022.1043551

102.

Morcos R, Al Taii H, Bansal P, Casale J, Manam R, Patel V et al (2018) Accuracy of Commonly-Used imaging modalities in assessing left atrial appendage for interventional closure: review Article. J Clin Med 7:441. https://doi.org/10.3390/jcm7110441CrossRefPubMedPubMedCentral

103.

Wang H, Ge L, Zhou H, Lu X, Yu Z, Peng P et al (2024) Radiomics prediction models of left atrial appendage hypercoagulability based on machine learning algorithms: an exploration about cardiac computed tomography angiography imaging. Int J Cardiovasc Imaging 40:2405–2415. https://doi.org/10.1007/s10554-024-03248-yCrossRefPubMed

Title: Left atrial appendage occlusion in patients with cancer
Authors: Nathaniel E. Davis
Samuel A. Shabtaie
Nicholas Y. Tan
Publication date: 05-04-2025
Publisher: Springer US
Keywords: Atrial Fibrillation
Heart Surgery
Heart Surgery
Thrombocytopenia
Heart Failure
Published in: Journal of Thrombosis and Thrombolysis
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-025-03098-y

Keynote series | Spotlight on managing health in obesity

Obesity
Video Series

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman

Prof. Jonette Keri

Developed by: Springer Medicine

Watch now

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Live
Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital

Prof. Ronald F. van Vollenhoven

Developed by: Springer Medicine

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Left atrial appendage occlusion in patients with cancer

Abstract

Keynote series | Spotlight on managing health in obesity

Women’s health knowledge hub

Keynote webinar | Spotlight on advances in lupus

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Abstract

Please log in to get access to this content

Keynote series | Spotlight on managing health in obesity

Women’s health knowledge hub

Keynote webinar | Spotlight on advances in lupus